Although CAF‐sEVs efficiently amplified the TGF‐β signalling activity in MCF7 cells in vitro, we asked whether the limited responsiveness of these breast cancer cells to TGF‐β would restrict similar outcomes in vivo. This evidence concerns the gene TGFB1 and breast carcinoma.